nanology.us Site Map
Pages
- About
- BIO CEO 2019: Reshaping Tumor Microenvironments via Immunotherapies
- Contact
- Development
- HOME
- Immune Response
- Legal
- NanOlogy in the News
- NanOlogy.us Cookie Policy
- News
- Presentations
- Press Releases
- Publications
- Site Map
- Technology
- Video: Highlights of NanoPac® Injection for Pancreatic Cancer
- Video: NanoPac® Injection for Pancreatic Cancer
Posts by category
- Category: Home Page
- NanOlogy Granted a US Patent for Its Investigational Drugs in Combination with Immune Checkpoint Inhibitors in the Treatment of Cancer
- NanOlogy Completes Enrollment in Phase 2a Trial of Intratumoral LSAM-PTX with SOC in Patients with Nonoperable Lung Cancer
- NanOlogy Publishes Review Article of Preclinical and Clinical Research Supporting LSAM-DTX
- NanOlogy Publishes Results from a Phase 1/2 Clinical Trial of Large Surface Area Microparticle Docetaxel in High-Risk Non-Muscle Invasive Bladder Cancer
- NanOlogy Publishes Results from a Phase 1/2 Clinical Trial of its Topical Investigational Drug in the Treatment of Cutaneous Metastases of Breast Cancer
- Improved Resection Rates in Locally Advanced Pancreatic Cancer Following Addition of Intratumoral NanoPac® to Standard of Care
- Medical Oncology: Submicron particle docetaxel intratumoral injection in combination with anti-mCTLA-4 into 4T1-Luc orthotopic implants reduces primary tumor and metastatic pulmonary lesions
- Additional Data Presented at DDW® 2021 from a Phase 2 Clinical Trial of Intracystic NanoPac® for Mucinous Cystic Neoplasms of the Pancreas
- NanOlogy Announces First Patient Enrollment in Lung Cancer Clinical Trial
- NanOlogy Completes Enrollment of Bladder Cancer Clinical Trial
- Drug Delivery and Translational Research: Local administration of submicron particle paclitaxel to solid carcinomas induces direct cytotoxicity and immune-mediated tumoricidal effects without local or systemic toxicity: preclinical and clinical studies
- NanOlogy Enrolls First Patient in Phase 2 Clinical Trial of NanoPac® for Intratumoral Treatment of Prostate Cancer
- Gynecologic Oncology Reports: Phase II study of intraperitoneal submicron particle paclitaxel (SPP) plus IV carboplatin and paclitaxel in patients with epithelial ovarian cancer surgery
- NanOlogy Announces Initiation of a Lung Cancer Clinical Trial Following FDA Allowances of Two IND Applications for NanoPac® in Lung Cancer
- Investigational New Drugs: Intratumoral Submicron Particle Docetaxel Inhibits Syngeneic Renca Renal Cancer Growth & Increases CD4+, CD8+ and Treg Levels in Peripheral Blood
- NanOlogy Clinical Updates on Local Injection of NanoPac® for Pancreatic Cancer and Mucinous Cystic Neoplasms of the Pancreas
- Video: NanoPac Injection for Pancreatic Cancer | Neil R. Sharma, MD, Parkview Cancer Institute (7-minute version)
- ACG 2019 Poster: NanoPac-2017-01 Mid-Study Report: Safety, Tolerability and Preliminary Efficacy of Intracyctic Submicron Particle Paclitaxel (SPP) for the Treatment of Pancreatic Mucinous Cysts
- Journal of Aerosol Medicine and Pulmonary Drug Delivery: Inhaled Submicron Particle Paclitaxel (NanoPac®) Induces Tumor Regression and Immune Cell Infiltration in an Orthotopic Athymic Nude Rat Model of Non-Small Cell Lung Cancer
- NanOlogy announces First Patient Enrolled in a Phase 1/2 Clinical Trial of NanoDoce® for Treatment of Bladder Cancer
- BIOCEO19 Video: Reshaping Tumor Microenvironments via Immunotherapies. Panel including Gere diZerega, MD, Chief Medical Officer of NanOlogy
- ASCO-GU19 Poster: Evaluation of Submicron Particle Docetaxel Directly Injected into Uro-Oncologic Xenografts
- NanOlogy Named to BioSpace Top 20 Life Science Startups to Watch in 2019
- Wuxi AppTec: Small Molecule Chemotherapy May Play a Big Role in Cancer Immunotherapy
- Category: NanOlogy Events
- June 2 : 9th Annual Immuno-Oncology Innovation Forum | Chicago
- June 2-6 : ASCO 2023 – American Society of Clinical Oncology | Chicago
- August 24-26 : AABIP – 6th Annual Conference of American Association for Bronchial and Interventional Pulmonology | Chicago
- September 27-30 : AACR Special Conference: Pancreatic Cancer | Boston
- November 1-5 : SITC – 38th Annual Meeting Society for Immunotherapy of Cancer | San Diego
- December 1-3 : IASLC 2023 – North American Conference on Lung Cancer| Chicago
- Category: NanOlogy in the News
- OncLive: LSAM-DTX Effective and Safe in NMIBC Using Direct, Multifaceted Approach
- Target Oncology: Direct and Multifaceted LSAM-DTX Treatment May Be Safe and Effective in NMIBC
- JACS: Surgery is a viable treatment for pancreatic cancer patients especially after chemotherapy
- Current Urology Reports: Current Clinical Trials in Non-muscle-Invasive Bladder Cancer: Heightened Need in an Era of Chronic BCG Shortage
- Drug Development Technology: NanOlogy Starts Enrollment in NanoDoce’s Phase I/II Trial
- Drug Development: Targeted Delivery of Submicron Particle Cancer Chemotherapy: Helping Shift the Immunotherapy Paradigm
- Drug Delivery: NanOlogy Touts Preclinical Data for Inhaled NanoPac Cancer Drug
- Boston Business Journal: NanOlogy Completes Dose Escalation Portion of Phase 2 Clinical Trial of NanoPac for Treatment of Prostate Cancer
- BioCentury: Tiny Taxanes – How Nanology’s Particle Production Technology Created Submicron Chemotherapy
- Drug Delivery: NanOlogy looks to transform chemotherapy with localized delivery platform
- Drug Development: NanOlogy Submicron Particle Platform Transforms Systemic Chemotherapy Into Local Delivery
- DermWire: NanOlogy Enrolls First Patient in Clinical Trial for Cutaneous Metastases
- Houston Business Journal: NanOlogy to Update Clinical Program at BIO CEO Conference
- PharmaVOICE: Next-Generation Nanomedicines
- Drug Delivery Business: NanOlogy takes nanoparticle tech into Phase II trials
- Clinical Leader: Trial Aims To Kill Cancer Without Chemotherapy Side Effects
- DDNEWS: New Cancer Answer
- Ovarian Cancer News: First Patient Enrolled in NanoPac Trial Evaluating New Anti-Cancer Treatment Delivery
- Journal for Clinical Studies: NanOlogy begins NanoPac’s phase 2 study to treat ovarian cancer
- Drug Delivery: NanOlogy takes nanoparticle tech into phase 2 trials.
- PBR: NanOlogy begins NanoPac’s phase 2 study to treat ovarian cancer
- Practical Dermatology: Update from DFB Soria on Enrollment in Phase 2 Clinical Trial of Nanoparticle Paclitaxel Ointment for AK
- DFB Pharmaceuticals Forms NanOlogy & Soria for Clinical Development of Naked Nanoparticle Platform
- Cancer Treatment: DFB Pharmaceuticals forms new company that could revolutionize cancer treatment
- ‘Bare’-ish on naked effort, Nanology unveils particle approach across cancers
- DFB Pharmaceuticals Forms NanOlogy™
- DFB Pharmaceuticals Forms NanOlogy™ for Clinical Development of Naked Nanoparticle Platform to Treat Cancer and Related Illnesses
- Category: NanOlogy Press Release
- NanOlogy Publishes Results From a Clinical Trial of Intracystic LSAM-PTX in Mucinous Pancreatic Cysts
- NanOlogy Presents Results of SOR007 (Topical Submicron Particle Paclitaxel) Phase 1/2 Clinical Trial in the Treatment of Cutaneous Metastases at 2020 SABCS®
- NanOlogy Presents Updated Clinical Data on Targeted Injections of NanoPac® for Pancreatic Cancer and Mucinous Cystic Neoplasms on DDW2020 Site
- NanOlogy to Present Interim Data for Pancreatic Cancer and Mucinous Cystic Neoplasms of the Pancreas with Local Injection of NanoPac®
- NanOlogy to Present Preclinical Lung Cancer Study Showing Inhaled NanoPac® Resulted in Increased Tumor Regression and Immune Response
- NanOlogy to Present Positive Preclinical Data for NanoDoce® in Treatment of Uro-Oncologic Cancers at 2019 Genitourinary Cancers (ASCO-GU) Symposium
- NanOlogy Chief Medical Officer on Panel to Discuss Next Wave of Innovation in IO Therapy at BIO CEO & Investor Conference
- Positive Preclinical Findings from Inhaled NanoPac® Lung Study Published in the Journal of Aerosol Medicine and Pulmonary Drug Delivery
- DFB Soria Completes a Phase 2 Clinical Trial of Submicron Particle Paclitaxel Anhydrous Ointment for Actinic Keratosis
- NanOlogy Adds Clinical Trial Sites for Phase 2 Clinical Trials of NanoPac® in Pancreatic Cancer and Pancreatic Mucinous Cysts
- NanOlogy to Unveil Positive Preclinical Data for Inhaled NanoPac® in Treatment of Lung Cancer at 2018 ASCO Annual Meeting
- NanOlogy Completes Dose Escalation Portion of Phase 2 Clinical Trial of NanoPac® for Treatment of Prostate Cancer
- NanOlogy to Present Abstract on Preclinical Study of Nebulized NanoPac for Lung Cancer at 2018 ASCO Annual Meeting
- NanOlogy Announces First Patient Enrolled in a Phase 2 Clinical Trial for Cutaneous Metastases and DFB Soria Provides an Update on AK Trial
- NanOlogy to Update Clinical Program Transforming Treatment of Cancer at BIO CEO and Investor Conference
- NanOlogy to Present Update on Cancer Treatment Clinical Program at Biotech Showcase in San Francisco
- NanOlogy Announces First Patient Enrolled in a Pancreatic Cancer Phase 2 Clinical Trial of NanoPac® Adding to Trials in Prostate and Ovarian Cancers
- NanOlogy Announces First Patient Enrolled in a Phase 2 Clinical Trial of NanoPac® for Treatment of Mucinous Cysts of the Pancreas
- NanOlogy Announces First Patient Enrolled in a Phase 2 Clinical Trial of NanoPac® for Treatment of Prostate Cancer
- NanOlogy Announces First Patient Enrolled in a Phase 2 Clinical Trial of NanoPac® for Ovarian Cancer
- DFB Soria Gives Update on Enrollment in Phase 2 Clinical Trial of SOR007 (Nanoparticle Paclitaxel) Ointment for Actinic Keratosis (AK)
- DFB Pharmaceuticals Forms NanOlogy™ for Clinical Development of Naked Nanoparticle Platform to Treat Cancer and Related Illnesses
- Category: Presentations
- DDW 2023 Poster: Intracystic Injection of Large Surface Area Microparticle Paclitael for Chemoablation of Intraductal Papillary Mucinous Neoplasms: Insights from an Expanded Access Protocol
- NanOlogy General Presentation (January 2023)
- DDW 2022 Poster: The Efficacy of Intracystic Injection of Large Surface Area Microparticle Paclitaxel (NanoPac®) in the Management of Intraductal Papillary Mucinous Neoplasms: Results from an Expanded Access Protocol
- ACG 2021 Presentation: Improved Resection Rates in Locally Advanced Pancreatic Cancer (LAPC) Following EUS-FNI of Large Surface Area Microparticle Paclitaxel (LSAM Pac)
- DDW 2021 Poster: Tandem EUS-Guided Fine Needle Injection of Intracystic Submicron Particle Paclitaxel (Nanopac®) as a Treatment for Branch-Duct IPMN: Safety, Pharmacokinetic, and Preliminary Efficiency
- SABCS 2020 Poster: Phase 1/2 Clinical Trial of A Topical Submicron Particle Paclitaxel (SOR007) for the Treatment of Cutaneous Metastases
- ASCO 2020 Abstract: Phase II study of intraperitoneal submicron particle paclitaxel (SPP) plus IV carboplatin and paclitaxel in patients with epithelial ovarian cancer undergoing cytoreductive surgery
- Digestive Disease Week 2020: Intracystic Injection of Submicron Particle Paclitaxel (SPP) for the Treatment of Mucinous Pancreatic Cystic Lesions Resulted in Reduction in Cyst Volume, an Interim Report (Mohamed O. Othman)
- Digestive Disease Week 2020: EUS-guided Injection of Intratumoral Submicron Particle Paclitaxel (SPP) for the Treatment of Locally Advanced Pancreatic Adenocarcinoma (LAPC) – Phase 2 Study (Neil Sharma, MD)
- Video Highlights: NanoPac Injection for Pancreatic Cancer | Neil R. Sharma, MD, Parkview Cancer Institute (3-minute version)
- ACG 2019 Plenary Presentation: A Novel EUS-guided Intratumoral Delivery of Submicron Particle Paclitaxel for the Treatment of Locally Advanced Pancreatic Cancer.
- ATS 2019 Poster: Enhanced Tumor Regression and Immune Cell Infiltration by Inhaled Submicron Particle Paclitaxel
- SABCS 2018 Poster: Phase 1/2 Study of Topical SOR007 for Cutaneous Metastases
- ASCO 2018 Poster: NanoPac Inhalation Treatment of NSCLC in a Nude Rat Orthotopic Lung Cancer Model
- Category: Publications
- Diagnostics: A Review of Endoscopic Ultrasound-Guided Chemoablative Techniques for Pancreatic Cystic Lesions
- Early phase trial of intracystic injection of large surface area microparticle paclitaxel for treatment of mucinous pancreatic cysts
- The Journal of Urology : Phase 1/2 Trial Results of a Large Surface Area Microparticle Docetaxel for the Treatment of High-Risk Nonmuscle-Invasive Bladder Cancer
- Drug Delivery and Translational Research : Local Administration of Large Surface Area Microparticle Docetaxel to Solid Carcinomas Induces Direct Cytotoxicity and Immune-mediated Tumoricidal Effects: Preclinical and Clinical Studies
- Respiratory Drug Delivery: Aggregated High Surface Area Particle Technology for Pulmonary Drug Delivery
- Endoscopic Ultrasound: An Update on EUS-Guided Ablative Techniques for Pancreatic Cyctic Lesions
- Breast Cancer Research & Treatment: Phase 1/2 Study of Topical Submicron Particle Paclitaxel for Cutaneous Metastases of Breast Cancer
- Cancers 2019: Local Injection of Submicron Particle Docetaxel is Associated with Tumor Eradication, Reduced Systemic Toxicity and an Immunologic Response in Uro-Oncologic Xenografts
- Journal of Aerosol Medicine and Pulmonary Drug Delivery: Pharmacokinetic Profile of Inhaled Submicron Particle Paclitaxel (NanoPac®) in a Rodent Model
- Cancer Chemotherapy & Pharmacology: Phase I study of intraperitoneal nanoparticulate paclitaxel (nanotax®) in patients with peritoneal malignancies
- Category: Soria
- Category: Uncategorized
